Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group

JACC: Basic to Translational Science

Volumn 1, Issue 1-2, 2016, Pages 73-86

  King, Kevin R ^a,b   Grazette, Luanda P ^c   Paltoo, Dina N ^d   McDevitt, John T ^e   Sia, Samuel K ^f   Barrett, Paddy M ^g   Apple, Fred S ^h   Gurbel, Paul A ⁱ   Weissleder, Ralph ^b   Leeds, Hilary ^d   Iturriaga, Erin J ^j   Rao, Anupama K ^j   Adhikari, Bishow ^j   Desvigne Nickens, Patrice ^j   Galis, Zorina S ^j   Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e RICE UNIVERSITY   (United States)

^f Department of Earth and Environmental Sciences   (United States)

^g SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^h UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

ⁱ INOVA HEART AND VASCULAR INSTITUTE   (United States)

^j NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

more..

Author keywords

biomarkers; clinical trials; precision medicine

Indexed keywords

EID: 85010424124     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2016.01.008     Document Type: Review

References (75)

1. 1 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001), 89–95.
2. 2 Armstrong, J.A., Urinalysis in Western culture: a brief history. Kidney Int 71 (2007), 384–387.
3. 3 Rosenfeld, L., Clinical chemistry since 1800: growth and development. Clin Chem 48 (2002), 186–197.
4. 4 National Institutes of Health. ACD Precision Medicine Initiative Working Group Public Workshop. Mobile and Personal Technologies in Precision Medicine Workshop. Available at: http://www.nih.gov/precisionmedicine/workshop-20150727.htm. Accessed February 12, 2016.
5. 5 Chin, C.D., Linder, V., Sia, S.K., Lab-on-a-chip devices for global health: past studies and future opportunities. Lab Chip 7 (2007), 41–57.
6. 6 Reddy, K.S., Cardiovascular disease in non-Western countries. N Engl J Med 350 (2004), 2438–2440.
7. 7 Chin, C.D., Laksanasopin, T., Cheung, Y.K., et al. Microfluidics-based diagnostics of infectious diseases in the developing world. Nat Med 17 (2011), 1015–1019.
8. 8 National Heart, Lung, and Blood Institute. Point-of-Care Technology for Cardiovascular Care. Available at: http://www.nhlbi.nih.gov/research/reports/2013-onsite-tools. Accessed February 12, 2016.
9. 9 Amundson, B.E., Apple, F.S., Cardiac troponin assays: a review of quantitative point-of-care devices and their efficacy in the diagnosis of myocardial infarction. Clin Chem Lab Med 53 (2015), 665–676.
10. 10 Body, R., Burrows, G., Carley, S., et al. High-sensitivity cardiac troponin t concentrations below the limit of detection to exclude acute myocardial infarction: a prospective evaluation. Clin Chem 61 (2015), 983–989.
11. 11 Carlton, E.W., Cullen, L., Than, M., Gamble, J., Khattab, A., Greaves, K., A novel diagnostic protocol to identify patients suitable for discharge after a single high-sensitivity troponin. Heart 101 (2015), 1041–1046.
12. 12 Rubini Gimenez, M., Twerenbold, R., Jaeger, C., et al. One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. Am J Med 128 (2015), 861–870.e4.
13. 13 Keller, T., Zeller, T., Ojeda, F., et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA 306 (2011), 2684–2693.
14. 14 Shah, A.S.V., Anand, A., Sandoval, Y., et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet 386 (2015), 2481–2488.
15. 15 Palamalai, V., Murakami, M.M., Apple, F.S., Diagnostic performance of four point of care cardiac troponin I assays to rule in and rule out acute myocardial infarction. Clin Biochem 46 (2013), 1631–1635.
16. 16 Furie, B., Furie, B.C., Mechanisms of thrombus formation. N Engl J Med 359 (2008), 938–949.
17. 17 Dahlen, J.R., Price, M.J., Parise, H., Gurbel, P.A., Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. Thromb Haemost 109 (2013), 808–816.
18. 18 Lipets, E.N., Ataullakhanov, F.I., Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. Thromb J, 13, 2015, 4.
19. 19 Welsh, K.J., Nedelcu, E., Bai, Y., et al. How do we manage cardiopulmonary bypass coagulopathy?. Transfusion 54 (2014), 2158–2166.
20. 20 Besser, M.W., Klein, A.A., The coagulopathy of cardiopulmonary bypass. Crit Rev Clin Lab Sci 47 (2010), 197–212.
21. 21 Chew, D.P., Bhatt, D.L., Lincoff, A.M., et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 103 (2001), 961–966.
22. 22 Price, M.J., Berger, P.B., Teirstein, P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305 (2011), 1097–1105.
23. 23 Price, M.J., Angiolillo, D.J., Teirstein, P.S., et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124 (2011), 1132–1137.
24. 24 Cohoon, K.P., Heit, J.A., Should platelet function testing guide antiplatelet therapy for patients with coronary artery stenting or acute coronary syndromes?. Clin Chem 59 (2013), 1299–1300.
25. 25 Ridker, P.M., Manson, J.E., Buring, J.E., Muller, J.E., Hennekens, C.H., Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 82 (1990), 897–902.
26. 26 Muller, J.E., Stone, P.H., Turi, Z.G., et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 313 (1985), 1315–1322.
27. 27 Skewis, L.R., Lebedeva, T., Papkov, V., et al. T2 magnetic resonance: a diagnostic platform for studying integrated hemostasis in whole blood—proof of concept. Clin Chem 60 (2014), 1174–1182.
28. 28 Jeong, Y.H., Bliden, K.P., Shuldiner, A.R., Tantry, U.S., Gurbel, P.A., Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thromb Haemost 111 (2014), 713–724.
29. 29 Lin, K.Y., Kwong, G.A., Warren, A.D., Wood, D.K., Bhatia, S.N., Nanoparticles that sense thrombin activity as synthetic urinary biomarkers of thrombosis. ACS Nano 7 (2013), 9001–9009.
30. 30 Warren, A.D., Kwong, G.A., Wood, D.K., Lin, K.Y., Bhatia, S.N., Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics. Proc Natl Acad Sci U S A 111 (2014), 3671–3676.
31. 31 Warren, A.D., Gaylord, S.T., Ngan, K.C., et al. Disease detection by ultrasensitive quantification of microdosed synthetic urinary biomarkers. J Am Chem Soc 136 (2014), 13709–13714.
32. 32 Rogers, M.L., Boutelle, M.G., Real-time clinical monitoring of biomolecules. Annu Rev Anal Chem (Palo Alto Calif) 6 (2013), 427–453.
33. 33 Ferguson, B.S., Hoggarth, D.A., Maliniak, D., et al. Real-time, aptamer-based tracking of circulating therapeutic agents in living animals. Sci Transl Med, 5, 2013, 213ra165.
34. 34 Snyder, T.M., Khush, K.K., Valantine, H.A., Quake, S.R., Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A 108 (2011), 6229–6234.
35. 35 De Vlaminck, I., Valantine, H.A., Snyder, T.M., et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med, 6, 2014, 241ra77.
36. 36 De Vlaminck, I., Khush, K.K., Strehl, C., et al. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell 155 (2013), 1178–1187.
37. 37 Elashoff, M.R., Wingrove, J.A., Beineke, P., et al. Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. BMC Med Genomics, 4, 2011, 26.
38. 38 Rosenberg, S., Elashoff, M.R., Beineke, P., et al. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med 153 (2010), 425–434.
39. 39 Sahoo, S., Losordo, D.W., Exosomes and cardiac repair after myocardial infarction. Circ Res 114 (2014), 333–344.
40. 40 Rayner, K., Dimmeler, S., Calin, G.A., Thum, T., Raizman, J.E., Diamandis, E.P., Novel biomarkers for acute myocardial infarction: is microRNA the new kid on the block?. Clin Chem 60 (2014), 812–817.
41. 41 Nagrath, S., Sequist, L.V., Maheswaran, S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450 (2007), 1235–1239.
42. 42 Nahrendorf, M., Swirski, F.K., Aikawa, E., et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 204 (2007), 3037–3047.
43. 43 Whitesides, G.M., The origins and the future of microfluidics. Nature 442 (2006), 368–373.
44. 44 Kumar, A.A., Hennek, J.W., Smith, B.S., et al. From the bench to the field in low-cost diagnostics: two case studies. Angew Chem Int Ed Engl 54 (2015), 5836–5853.
45. 45 Thorsen, T., Maerkl, S.J., Quake, S.R., Microfluidic large-scale integration. Science 298 (2002), 580–584.
46. 46 Unger, M.A., Chou, H.P., Thorsen, T., Scherer, A., Quake, S.R., Monolithic microfabricated valves and pumps by multilayer soft lithography. Science 288 (2000), 113–116.
47. 47 Im, H., Shao, H., Park, Y.I., et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol 32 (2014), 490–495.
48. 48 Haun, J.B., Castro, C.M., Wang, R., et al. Micro-NMR for rapid molecular analysis of human tumor samples. Sci Transl Med, 3, 2011, 71ra16.
49. 49 Lee, H., Sun, E., Ham, D., Weissleder, R., Chip-NMR biosensor for detection and molecular analysis of cells. Nat Med 14 (2008), 869–874.
50. 50 Im, H., Castro, C.M., Shao, H., et al. Digital diffraction analysis enables low-cost molecular diagnostics on a smartphone. Proc Natl Acad Sci U S A 112 (2015), 5613–5618.
51. 51 Evans, J.M.M., Mackison, D., Swanson, V., Donnan, P.T., Emslie-Smith, A., Lawton, J., Self-monitoring among non-insulin treated patients with type 2 diabetes mellitus: patients’ behavioural responses to readings and associations with glycaemic control. Diabetes Res Clin Pract 100 (2013), 235–242.
52. 52 Parkin, C.G., Davidson, J.A., Value of self-monitoring blood glucose pattern analysis in improving diabetes outcomes. J Diabetes Sci Technol 3 (2009), 500–508.
53. 53 St John, A., Davis, W.A., Price, C.P., Davis, T.M.E., The value of self-monitoring of blood glucose: a review of recent evidence. J Diabetes Complications 24 (2010), 129–141.
54. 54 Stratton, I.M., Adler, A.I., Neil, H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000), 405–412.
55. 55 St John, A., Evidence to support point-of care-testing. Clin Biochem Rev 31 (2010), 111–119.
56. 56 Heneghan, C., Ward, A., Perera, R., et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 379 (2012), 322–334.
57. 57 Kim, D.H., Lu, N., Ma, R., et al. Epidermal electronics. Science 333 (2011), 838–843.
58. 58 Xu, S., Zhang, Y., Jia, L., et al. Soft microfluidic assemblies of sensors, circuits, and radios for the skin. Science 344 (2014), 70–74.
59. 59 Zimetbaum, P., Waks, J.W., Ellis, E.R., Glotzer, T.V., Passman, R.S., Role of atrial fibrillation burden in assessing thromboembolic risk. Circ Arrhythm Electrophysiol 7 (2014), 1223–1229.
60. 60 Yiin, G.S., Howard, D.P., Paul, N.L., et al. Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation 130 (2014), 1236–1244.
61. 61 Zimetbaum, P., Goldman, A., Ambulatory arrhythmia monitoring: choosing the right device. Circulation 122 (2010), 1629–1636.
62. 62 Chaudhry, S.I., Phillips, C.O., Stewart, S.S., et al. Telemonitoring for patients with chronic heart failure: a systematic review. J Card Fail 13 (2007), 56–62.
63. 63 Desai, A.S., Stevenson, L.W., Rehospitalization for heart failure: predict or prevent?. Circulation 126 (2012), 501–506.
64. 64 Chaudhry, S.I., Mattera, J.A., Curtis, J.P., et al. Telemonitoring in patients with heart failure. N Engl J Med 363 (2010), 2301–2309.
65. 65 Hafezi, H., Robertson, T.L., Moon, G.D., Au-Yeung, K.Y., Zdeblick, M.J., Savage, G.M., An ingestible sensor for measuring medication adherence. IEEE Trans Biomed Eng 62 (2015), 99–109.
66. 66 Laksanasopin, T., Guo, T.W., Nayak, S., et al. A smartphone dongle for diagnosis of infectious diseases at the point of care. Sci Transl Med, 7, 2015, 273re1.
67. 67 Yamokoski, L.M., Haas, G.J., Gans, B., Abraham, W.T., OptiVol fluid status monitoring with an implantable cardiac device: a heart failure management system. Expert Rev Med Devices 4 (2007), 775–780.
68. 68 Brachmann, J., Bohm, M., Rybak, K., et al. Fluid status monitoring with a wireless network to reduce cardiovascular-related hospitalizations and mortality in heart failure: rationale and design of the OptiLink HF Study (Optimization of Heart Failure Management using OptiVol Fluid Status Monitoring and CareLink). Eur J Heart Fail 13 (2011), 796–804.
69. 69 Crozier, I., Smith, W., Modern device technologies. Heart Lung Circ 21 (2012), 3206–3207.
70. 70 Teerlink, J.R., Learning the points of COMPASS-HF: assessing implantable hemodynamic monitoring in heart failure patients. J Am Coll Cardiol 51 (2008), 1080–1082.
71. 71 Bourge, R.C., Abraham, W.T., Adamson, P.B., et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 51 (2008), 1073–1079.
72. 72 Abraham, W.T., Adamson, P.B., Bourge, R.C., et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377 (2011), 658–666.
73. 73 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. Draft guidance for industry, Food and Drug Administration Staff, and Clinical Laboratories: framework for regulatory oversight of laboratory developed tests (LDTs). 2014. Available at: http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm416685.pdf. Accessed February 5, 2016.
74. 74 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, and Center for Biologics Evaluation and Research. Mobile medical applications: guidance for industry and Food and Drug Administration Staff. 2015. Available at: http://www.fda.gov/downloads/MedicalDevices/…/UCM263366.pdf. Accessed February 5, 2016.
75. 75 HealthIT.gov. HIPAA and Health IT. Available at: http://www.healthit.gov/policy-researchers-implementers/hipaa-and-health-it. Accessed February 12, 2016.